FULGENT GENETICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
FULGENT GENETICS, INC. (FLGT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$29.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-07-30
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$29.53M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$24.83M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$23.42M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$6.61M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$60.51M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$42.71M.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$167.82M, a 217.03% decline from fiscal 2022.
- FULGENT GENETICS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $143.40M, a 71.74% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 2 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$29.53M 10-Q · filed 2026-07-30 | -$54.36M 10-Q · filed 2026-07-30 | -$77.77M derived: sum of 3 quarters · filed 2026-07-30 | -$84.38M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$24.83M 10-Q · filed 2026-05-01 | -$48.24M derived: sum of 2 quarters · filed 2026-05-01 | -$54.85M derived: sum of 3 quarters · filed 2026-05-01 | -$73.81M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$23.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$30.03M derived: sum of 2 quarters · filed 2026-02-27 | -$48.98M derived: sum of 3 quarters · filed 2026-07-30 | -$60.51M 10-K · filed 2026-02-27 | |
| 2025-09-30 | -$6.61M 10-Q · filed 2025-11-07 | -$25.57M derived: sum of 2 quarters · filed 2026-07-30 | -$37.09M 10-Q · filed 2025-11-07 | -$42.98M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$18.96M 10-Q · filed 2026-07-30 | -$30.49M 10-Q · filed 2026-07-30 | -$36.38M derived: sum of 3 quarters · filed 2026-07-30 | -$51.02M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$11.53M 10-Q · filed 2026-05-01 | -$17.42M derived: sum of 2 quarters · filed 2026-05-01 | -$32.07M derived: sum of 3 quarters · filed 2026-05-01 | -$40.78M derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | -$5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$20.54M derived: sum of 2 quarters · filed 2026-02-27 | -$29.25M derived: sum of 3 quarters · filed 2026-02-27 | -$42.71M 10-K · filed 2026-02-27 | |
| 2024-09-30 | -$14.65M 10-Q · filed 2025-11-07 | -$23.36M derived: sum of 2 quarters · filed 2025-11-07 | -$36.82M 10-Q · filed 2025-11-07 | -$164.97M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | -$8.71M 10-Q · filed 2025-08-01 | -$22.17M 10-Q · filed 2025-08-01 | -$150.32M derived: sum of 3 quarters · filed 2026-02-27 | -$163.43M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | -$13.46M 10-Q · filed 2025-05-02 | -$141.61M derived: sum of 2 quarters · filed 2026-02-27 | -$154.72M derived: sum of 3 quarters · filed 2026-02-27 | -$165.95M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | -$128.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$141.26M derived: sum of 2 quarters · filed 2026-02-27 | -$152.49M derived: sum of 3 quarters · filed 2026-02-27 | -$167.82M 10-K · filed 2026-02-27 | |
| 2023-09-30 | -$13.11M 10-Q · filed 2024-11-08 | -$24.34M derived: sum of 2 quarters · filed 2024-11-08 | -$39.68M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | -$11.23M 10-Q · filed 2024-08-02 | -$26.57M 10-Q · filed 2024-08-02 | |||
| 2023-03-31 | -$15.34M 10-Q · filed 2024-05-03 | ||||
| 2022-12-31 | $143.40M 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $507.36M 10-K · filed 2024-02-28 | ||||
| 2017-12-31 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$2.72M derived: sum of 2 quarters · filed 2018-03-20 | -$2.74M derived: sum of 3 quarters · filed 2018-03-20 | -$2.51M 10-K · filed 2018-03-20 | |
| 2017-09-30 | -$1.09M 10-Q · filed 2017-11-13 | -$1.12M derived: sum of 2 quarters · filed 2017-11-13 | -$886.00K 10-Q · filed 2017-11-13 | -$73.00K derived: sum of 4 quarters · filed 2018-03-20 | |
| 2017-06-30 | -$25.00K 10-Q · filed 2017-08-14 | $207.00K 10-Q · filed 2017-08-14 | $1.02M derived: sum of 3 quarters · filed 2018-03-20 | -$4.68M derived: sum of 4 quarters · filed 2018-03-20 | |
| 2017-03-31 | $232.00K 10-Q · filed 2017-05-09 | $1.04M derived: sum of 2 quarters · filed 2018-03-20 | -$4.65M derived: sum of 3 quarters · filed 2018-03-20 | -$12.89M derived: sum of 4 quarters · filed 2018-03-20 | |
| 2016-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$4.89M derived: sum of 2 quarters · filed 2018-03-20 | -$13.12M derived: sum of 3 quarters · filed 2018-03-20 | -$13.67M 10-K · filed 2018-03-20 | |
| 2016-09-30 | -$5.70M 10-Q · filed 2017-11-13 | -$13.94M derived: sum of 2 quarters · filed 2017-11-13 | -$14.48M 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | -$8.24M 10-Q · filed 2017-08-14 | -$8.78M 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | -$543.00K 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | -$8.13M 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |